Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

NCT00738673 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: degarelix

Sponsor

Ferring Pharmaceuticals